Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 31, 2022Malaria JournalOpen Access

Efficacy and safety of pyronaridine-artesunate (Pyramax®) for the treatment of uncomplicated Plasmodium vivax malaria in Northwest Ethiopia

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHussein MohammedLinköping UniversityHSHeven SimeEthiopian Public Health InstituteHHHenok HailgiorgisEthiopian Public Health Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mohammed et al. (2022) studied this question.

synapsesocial.com/papers/6ab4d4e77564dd65b94f57bahttps://doi.org/10.1186/s12936-022-04422-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine–artesunate in a rural health district in Burkina Faso2022 · 5 citations
  2. 2Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study2021 · 51 citations
  3. 3Genotyping of Plasmodium falciparum using antigenic polymorphic markers and to study anti-malarial drug resistance markers in malaria endemic areas of Bangladesh2012 · 27 citations
  4. 4Failure of chloroquine treatment for malaria in the highlands of Ethiopia1996 · 47 citations
  5. 5Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials2020 · 15 citations